Tuesday, June 21, 2016 12:44:10 PM
INSY ...TARGET-$22 MEDICAL MARIJUANA, synthesized marijuana cannabidiol
Buy Insys Therapeutics Before Medical Marijuana Reaches A Tipping Point
http://www.forbes.com/sites/kenkam/2016/06/21/buy-insys-therapeutics-before-medical-marijuana-reaches-a-tipping-point/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix#39c525b161f8
The medical marijuana trend has very quietly spread throughout the United States. Most people don’t realize that half of the United States has now approved medical marijuana laws, along with Washington D.C. medical marijuana accounted for just over $4 billion in revenue in 2015, but is expected to exceed $22 Billion by 2020. The ramifications of more states legalizing medical marijuana will have an exponential effect, because as it moves from the fringe to the mainstream, the results will grow dramatically faster than the adoption rate among states.
Four analysts follow the stock, at the moment. Three of them rate it a strong buy, and one rates it a hold. The average 12 month price target is $22/share, which represents a 37.5% increase over today’s prices. Overall, there is not a lot of attention on this stock, but the folks who are paying attention are very bullish on it’s prospects.
-------------------------------
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is Syndros, an orally administered liquid formulation of dronabinol. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.
60 MINUTE...
DAILY...oversold at support...
INSY
Buy Insys Therapeutics Before Medical Marijuana Reaches A Tipping Point
http://www.forbes.com/sites/kenkam/2016/06/21/buy-insys-therapeutics-before-medical-marijuana-reaches-a-tipping-point/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix#39c525b161f8
The medical marijuana trend has very quietly spread throughout the United States. Most people don’t realize that half of the United States has now approved medical marijuana laws, along with Washington D.C. medical marijuana accounted for just over $4 billion in revenue in 2015, but is expected to exceed $22 Billion by 2020. The ramifications of more states legalizing medical marijuana will have an exponential effect, because as it moves from the fringe to the mainstream, the results will grow dramatically faster than the adoption rate among states.
Four analysts follow the stock, at the moment. Three of them rate it a strong buy, and one rates it a hold. The average 12 month price target is $22/share, which represents a 37.5% increase over today’s prices. Overall, there is not a lot of attention on this stock, but the folks who are paying attention are very bullish on it’s prospects.
-------------------------------
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is Syndros, an orally administered liquid formulation of dronabinol. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.
60 MINUTE...
DAILY...oversold at support...
INSY
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
